Plus therapeutics expands management team and reports $3.3m advance payment from cprit

Greg fuller, m.d., ph.d., former professor of pathology (neuro-pathology) & neuro-radiology at the university of texas md anderson cancer center joins plus as vice president of medical affairs and medical director plus receives notice of an additional $3.3 million cprit advance payment for leptomeningeal cancer targeted radiotherapeutic development program austin, texas, june 07, 2024 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (“plus” or the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (cns) cancers, announced the appointment of dr. greg fuller as the company's vice president of medical affairs and medical director.
PSTV Ratings Summary
PSTV Quant Ranking